NCT00431678已完成3 期
A Multinational, Prospective, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Treatment of Patients With Severe Community-acquired Pneumonia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 738
- 主要终点
- Clinical response
研究概览
简要总结
Sequential therapy with intravenous to oral moxifloxacin, was tested at 69 study centres in 17 countries to determine if this treatment regimen is safe and effective in treating hospitalized adult patients with community-acquired pneumonia. 748 patients were participated in the study over an 18 months period. Individual patient involvement in the study was approximately 4-6 weeks. Moxifloxacin was compared to a combination treatment regimen of high dose intravenous ceftriaxone plus high dose intravenous levofloxacin followed by high dose oral levofloxacin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 years or above
- •All of the following signs and symptoms of pneumonia:
- •Fever (core/ rectal/ tympanic temperature >/= 38.5°C or axillary/ oral/ cutaneous temperature >/= 38.0°C) or hypothermia (core/ rectal/ tympanic temperature </= 35.5°C or axillary/ oral/ cutaneous temperature </= 35.0°C)
- •White blood cell (WBC) count > 10,000/µL, or >/= 15% immature neutrophils (bands), regardless of the peripheral WBC count, or total WBC count < 4,500/µL
- •The presence of at least 2 of the following symptoms: - Cough- Purulent sputum production
- •Dyspnoea or tachypnoea (respiratory rate > 20 breaths/minute)
- •Rigors and/or chills- Chest pain
- •Auscultatory findings on pulmonary examination of rales/crackles and/or evidence of pulmonary consolidationAND
- •Radiological evidence of (an) infiltrate(s) consistent with bacterial pneumonia at baseline or within 24 hours following enrolment
- •Fine score >/= 71 (i.e. Pneumonia PSI risk Class III, IV or V, requiring hospitalisation for the treatment of CAP)
- •Written informed consent obtained from the patient or a next-of-kin
排除标准
- •Known hypersensitivity to fluoroquinolones, or other quinolones, and/or to beta-lactams, or any of the excipients
- •Female patients who are pregnant or lactating
- •History of tendon disease/disorder related to quinolone treatment
- •Known congenital or documented-acquired QT prolongation; concomitant use of drugs, reported to increase the QT interval; uncorrected hypokalaemia; clinically relevant bradycardia; clinically relevant heart failure with reduced left
- •ventricular ejection fraction; previous history of symptomatic arrhythmias
- •History of epilepsy- Known glucose-6-phosphate dehydrogenase deficiency
- •Known severe impaired liver function (i.e. Child Pugh C), (refer to Section 10.4 for definition) or transaminases increase > 5 fold ULN- Hospitalisation for > 48 hours before developing pneumonia, or discharge from hospital < 30 days prior- Systemic antibacterial therapy for more than 24 hours within 14 days of enrolment
- •Patients requiring concomitant systemic antibacterial agents
- •Known structural lung disease (e.g. cystic fibrosis, bronchiectasis, or lung cancer), or other known conditions (e.g. malnutrition) predisposing to infection with nosocomial-like organisms such as Pseudomonas aeruginosa
- •Lung abscess, pleural empyema, risk factors for aspiration pneumonia (e.g. recent stroke, head injury, dementia)
- •Known rapidly fatal underlying disease (death expected within 6 months)
- •Known or suspected active tuberculosis or endemic fungal infection- Neutropenia (neutrophil count < 1,000/µL) caused by immunosuppressive therapy or malignancy
- •Patients known to have AIDS (CD4 count < 200/µL) or HIV-seropositive patients receiving HAART
- •Previous enrolment in this study
- •Participation in any clinical investigational drug study within the previous 4 weeks
- •Patient with pre-terminal renal failure (creatinine clearance < 10 mL/min) and patients undergoing haemodialysis
研究组 & 干预措施
Arm 1
Experimental
干预措施: Avelox (Moxifloxacin, BAY12-8039) (Drug)
Arm 2
Active Comparator
干预措施: Levofloxacin + Ceftriaxone (Drug)
结局指标
主要结局
Clinical response
时间窗: 5 to 7 days after last dose of study medication
次要结局
- Clinical and bacteriological response on treatment(At day 3 to 5)
- Mortality attributable to pneumonia(5-7 days after end of treatment)
- Symptoms course of community-acquired pneumonia(at defined visits)
- Clinical and bacteriological response(At days 21 to 28 after end of treatment)
- Bacteriological response(5-7 days after end of treatment)
- Adverse Event Collection(all visits)
研究者
相似试验
已完成
3 期
A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired PneumoniaPneumoniaNCT00717561Bayer60
已完成
3 期
Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal InfectionIntraabdominal InfectionsNCT01069900Bayer458
已完成
3 期
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIsInfectious DiseasesNCT00828971Bayer16
已完成
3 期
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic BronchitisLung DiseasesBronchitis, ChronicNCT00473460Bayer1,404
已完成
3 期
BAY12-8039, iv/Oral Pulmonary Abscess/Aspiration PneumoniaPneumonia, AspirationLung AbscessNCT01045902Bayer139